Seagen Inc.: European Commission Approves PADCEV (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor - Astellas Pharma Inc. (TSE:4503, President